Thetis Pharma

A biopharmaceutical company developing novel therapies for inflammatory diseases

[Thetis Pharma @thetispharma]

We are excited to announce our partnership with the @HelmsleyTrust to advance our first-in-class Resolvin oral therapy TP-317 into clinical development for Crohn's disease.

[Helmsley Charitable Trust @HelmsleyTrust]

Helmsley is proud to announce a program-related investment loan to @thetispharma to support the development of a drug with a novel mechanism to promote the resolution of inflammation and intestinal healing for people with Crohn’s disease. Read more here: https://t.co/xiYTDRUuJT

[Thetis Pharma @thetispharma]

Great article referencing Thetis Resolvin-based therapies for cancer treatment.

“Chemotherapy and radiation... may kill the tumor, but the debris they create stimulates inflammation, which feeds circulating tumor cells that survive the treatment.” - Dr. Dipak Panigrahy, Harvard.

[National Geographic @NatGeo]

Cancer, aging, and severe COVID-19 have all been linked to damage from inflammation. Now scientists are flipping their focus to find new drugs that may revolutionize treatments https://t.co/O0yCMvAIRC

[NewHavenBiz @NewHavenBiz]

FDA designates Thetis pancreatic cancer treatment ‘orphan drug’ / https://t.co/fq90bY3A3C @thetispharma #cancer

[Kenneth Rainin Foundation @KR_Foundation]

Our Health strategies aim to support translational science that will bring clinical applications to patients sooner. We invested in @thetispharma's development of a new therapy for ulcerative colitis, which now has FDA orphan drug designation. https://t.co/AIx3nDX5Tb

[Thetis Pharma @thetispharma]

We are excited to announce the launch of our Resolvin E1 program in cancer and scientific advisory board @DrMhidalgo @EileenMOReilly https://t.co/fRTh9iOt5T

[Thetis Pharma @thetispharma]

We are excited to announce the completion of an important regulatory milestone for our company. This is a major step towards advancing our Resolvin E1 therapy (TP-317) into clinical development for inflammatory bowel disease.
https://t.co/JlB8MqeJ8j

[BDLevy AIR Lab @BDLevyLab]

Bruce Levy and @CNSerhanLab "suggest that resolvins and protectins could be helpful in reducing the cytokine storm and lung damage in COVID-19" in an article titled "Resolving Inflammation" in @HarvardMagazine @BrighamResearch

Check it out: https://t.co/wNLpVl0KZH

[UConn Technology Commercialization Services @UConnTechComm]

TIP Spotlight: @thetispharma is a biopharmaceutical company that is developing novel drugs for treatment of inflammation-related gastrointestinal (GI) diseases with high unmet medical needs.

Learn More: https://t.co/P80qFlQMSz

@UConnResearch

[Thetis Pharma @thetispharma]

Watch our CEO, Gary Mathias, present on Non-immunosuppressive Therapies for Gastrointestinal Diseases at the @NobleFinancial Investor Conference this week. #noblecon16 #biotechnology #investing https://t.co/aVi4yd3pjg

[Thetis Pharma @thetispharma]

Thetis receives funding from the @CrohnsColitisFn to support investigational IBD therapy based on promising research from Dr. Charles Serhan (@CNSerhanLab) from @BrighamWomens #ibd #ulcerativecolitis #crohns @BrighamGI @BrighamResearch https://t.co/ZW2riLLnbO

[Thetis Pharma @thetispharma]

Pleased to announce that we have received a $2.3 million grant from the NIH to support a novel program in non-alcoholic steatohepatitis (NASH). This award diversifies our portfolio and further validates our HEALER technology platform.

https://t.co/UEtNCvBszo

[Thetis Pharma @thetispharma]

Thank you @KR_Foundation for hosting Thetis at the #InnovationsSymposium2019! https://t.co/E3YRds0ldj

[UConn Technology Commercialization Services @UConnTechComm]

👀 TIP company @thetispharma at #BIO2019
https://t.co/q0yYOQI9G5

[Thetis Pharma @thetispharma]

Thetis Presents Preclinical Data at DDW Showing Efficacy of TP-317 in Ulcerative Colitis and Crohn’s Disease Models with Unique Mucosal Healing MOA #DDW #IBD #ulcerativecolitis #crohnsdisease #resolution #mucosalhealing https://t.co/ad2n9BDlhA

[Thetis Pharma @thetispharma]

Dr. Ronald Lennox, an experienced biotechnology entrepreneur and investor, has joined our Board of Directors. https://t.co/hjNQYEUcRK

[Thetis Pharma @thetispharma]

Professor Charles Serhan (Brigham/Harvard), a pioneer in resolution pharmacology, has joined our SAB https://t.co/nNU1LoTJvd
#biotechnology #Resolvins #resolution #Harvard

[Thetis Pharma @thetispharma]

Thetis awarded key patents on TP-317 and other Resolvins
https://t.co/pZGIUj0Ire

[Thetis Pharma @thetispharma]

We are very excited to present the promising findings on TP-317 from a translational study using IBD patient tissue. This is a critical step on our path to clinical investigation. https://t.co/KSlfYMLYZ3

[Thetis Pharma @thetispharma]

Thetis awarded key patent on HEALER technology https://t.co/npFXtRKtug

[Thetis Pharma @thetispharma]

Enjoyed presenting at SAPA’s Philadelphia area Venture Forum. Great opportunity to learn about the convergence of Chinese and U.S. biotech and speak with potential investors.